Sandoz Inc.'s application package for its biosimilar to Amgen Inc.'s Enbrel continues to signal to FDA that the company is ready to move forward on interchangeability even if the agency is not.
A clinical study with multiple switches between GP2015 and its reference product was part of Sandoz's application to determine it is biosimilar to the tumor necrosis factor blocker
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?